December 11, 2017
Immunotherapy could be beneficial for relapsed acute myeloid leukemia
Researchers led by UNC Lineberger's Joshua Zeidner, MD, presented preliminary results from an ongoing phase II trial of the checkpoint inhibitor pembrolizumab and chemotherapy for relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta.